ALDO MEJIA: Open Payments
NPI 1922443381 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$279 in 11 payments from 9 companies in 2025. Trend: 2023 $63 · 2024 $137 · 2025 $279
Food & beverage: $240Education: $39
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 2 | $67 |
| Janssen Pharmaceuticals, Inc | 2 | $44 |
| Lundbeck LLC | 1 | $39 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Corium, LLC | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| ABBVIE INC. | 1 | $17 |
Products named: REXULTI, Qelbree, SPRAVATO, CAPLYTA, Azstarys, Jornay PM, VRAYLAR.
Industry payments across LA — which companies pay providers there.
